Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Itacnosertib - Sumitomo Pharma America

Next Previous
X
Search
Drug Profile

Itacnosertib - Sumitomo Pharma America

Alternative Names: Itacnosertib - Sumitomo Dainippon Pharma Oncology; TP-0184

Latest Information Update: 28 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tolero Pharmaceuticals
  • Developer Sumitomo Pharma America
  • Class Amines; Antianaemics; Antineoplastics; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action ACVR1 protein inhibitors; Transforming growth factor beta type I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia
  • No development reported Solid tumours
  • Discontinued Anaemia

Most Recent Events

  • 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO)
  • 30 Mar 2023 Sumitomo Pharma Oncology terminates a phase I/II trial in Anaemia (Treatment-resistant) in USA (PO) due to limitations imposed by the COVID pandemic and the competitive landscape for myelodysplastic syndrome (NCT04623996)
  • 10 Dec 2022 Pharmacodynamics data from a preclinical study in Acute myeloid leukemia presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top